9OF Stock Chart & Stats
€0.24
-€0.01(-5.56%)
At close: 4:00 PM EDT
€0.24
-€0.01(-5.56%)
Day’s Range― - ―
52-Week Range€0.13 - €1.66
Previous CloseN/A
Volume0.00
Average Volume (3M)158.00
Market Cap
€4.74M
Enterprise Value€1.27
Total Cash (Recent Filing)€3.59M
Total Debt (Recent Filing)€34.52K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume238
30 Day Avg. Volume158
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.29
Revenue Forecast (FY)€2.19M
Bulls Say, Bears Say
Bulls Say
Low LeverageEffectively no debt limits interest expense and reduces balance-sheet pressure, giving the company more flexibility than a highly leveraged biotech while it develops therapies and seeks a path toward commercialization.
Gross Margin PotentialThe solid gross margin indicates that the company’s offerings can generate positive economics after direct costs. If revenue expands, this provides a foundation for operating leverage, although current scale remains insufficient to cover overhead.
Board Oversight ExpertiseReinforcing independent oversight with pharmaceutical, regulatory and technology experience could improve governance and commercialization decisions, helping the company address compliance requirements and execute its regenerative-medicine strategy more effectively.
Bears Say
Shrinking Revenue And Deep LossesVery low and declining revenue leaves the business far from covering its cost base. The extreme net loss and negative operating results indicate that meaningful commercialization or substantial cost reduction is required before the model can become sustainable.
Persistent Cash BurnOngoing cash consumption materially exceeds the current revenue base and has worsened versus prior years. Continued reliance on external funding may create dilution, financing costs or operational constraints while clinical and commercial programs advance.
Regulatory And Listing UncertaintyA delayed regulatory filing raises confidence and execution concerns and creates a potential path toward Nasdaq delisting if compliance is not restored. The need to prepare a compliance plan may also divert scarce management and financial resources.
BioRestorative Therapies News
9OF FAQ
What was BioRestorative Therapies’s price range in the past 12 months?
BioRestorative Therapies lowest stock price was €0.13 and its highest was €1.66 in the past 12 months.
What is BioRestorative Therapies’s market cap?
BioRestorative Therapies’s market cap is €4.74M.
When is BioRestorative Therapies’s upcoming earnings report date?
BioRestorative Therapies’s upcoming earnings report date is Nov 18, 2026 which is in 82 days.
How were BioRestorative Therapies’s earnings last quarter?
Currently, no data Available
Is BioRestorative Therapies overvalued?
According to Wall Street analysts BioRestorative Therapies’s price is currently Overvalued.
Does BioRestorative Therapies pay dividends?
BioRestorative Therapies does not currently pay dividends.
What is BioRestorative Therapies’s EPS estimate?
BioRestorative Therapies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioRestorative Therapies have?
BioRestorative Therapies has 25,478,170 shares outstanding.
What happened to BioRestorative Therapies’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioRestorative Therapies?
Currently, no hedge funds are holding shares in DE:9OF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioRestorative Therapies
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.